{"id":"fractional-ipv-fipv","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"fIPV contains the same inactivated poliovirus antigens as standard IPV but at one-fifth the standard dose, administered intradermally or as a fractional dose. This approach maintains immunogenicity while reducing antigen requirements, making it suitable for resource-limited settings and contributing to polio eradication efforts by stretching vaccine supply.","oneSentence":"Fractional IPV (fIPV) is a reduced-dose inactivated polio vaccine that provides immunological protection against poliovirus while using a smaller antigen quantity per dose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:54.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants and children"}]},"trialDetails":[{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT04063150","phase":"PHASE4","title":"Immunogenicity of Intramuscular and Intradermal IPV","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-06","conditions":"Poliomyelitis","enrollment":958},{"nctId":"NCT03890497","phase":"PHASE4","title":"Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-09-27","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT03722004","phase":"PHASE4","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-12-18","conditions":"Poliomyelitis","enrollment":1256},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT03922061","phase":"PHASE1","title":"Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2019-03-19","conditions":"Polio","enrollment":29},{"nctId":"NCT03286803","phase":"PHASE4","title":"Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2017-08-01","conditions":"Poliovirus Vaccine, Inactivated, Poliomyelitis, Immunization; Infection","enrollment":500},{"nctId":"NCT02967783","phase":"NA","title":"A Campaign-based ID fIPV Administration Trial","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2017-02-07","conditions":"Poliomyelitis","enrollment":2721},{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144},{"nctId":"NCT02769923","phase":"NA","title":"ID Administration of fIPV Using Intradermal Adapters vs. BCG Syringe","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2015-09","conditions":"IPV","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fractional IPV( fIPV)","genericName":"Fractional IPV( fIPV)","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fractional IPV (fIPV) is a reduced-dose inactivated polio vaccine that provides immunological protection against poliovirus while using a smaller antigen quantity per dose. Used for Poliomyelitis prevention in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}